Overview

Levetiracetam 750 mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the rate and extent of absorption of a test formulation of Levetiracetam and the reference Keppra® administered as a 1 x 750 mg tablet under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Etiracetam
Levetiracetam
Piracetam